AV

Avicedarx

4 known investors

avicedarx.com ↗

Avicedar develops glyco-immune checkpoint therapeutics to treat immune-mediated diseases, with an initial focus on Macular Degeneration. The company operates in the biotechnology and drug development sector.

Investors · 4

JE

Jeito CapitalParis

LO

Longitude CapitalMenlo Park · $10M – $30M

OR

OrbiMedNew York · $1M – $75M

DI

Digitalis VenturesreportedNew York · $100K – $10M